Aquestive Therapeutics 주식 (NASDAQ: AQST)

Aquestive Therapeutics (NASDAQ:AQST) 주식

AQUESTIVE THERAPEUTICS INC

Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics Inc

New program enables issuers to enhance commercial offerings through fully integrated digital solutions
Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), a global leader in digital payments, announced Visa Commercial Integrated Partners, a new program designed to improve connectivity between fintechs and Visa Commercial products through its commercial platform. Visa will make available advanced APIs to embed Visa products in a business partners' applications and make these integrations available to its financial institution clients, allowing them to offer new, seamless payment experiences to their business customers.

News

Visa Announces Visa Commercial Integrated Partners, New Program To Improve Connectivity Between Fintechs And Visa Commercial Products Through Its Commercial Platform

Magic Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGIC#NASDAQ">MGIC</a>) reported quarterly earnings of $0.25 per share which met the analyst consensus estimate. This is a 8.7 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $147.30 million which beat the analyst consensus estimate of $143.79 million by 2.44 percent. This is a 12.68 percent increase over sales of $130.72 million the same period last year.

Earnings

Earnings Beats

MGIC

Magic Software Q1 Adj. EPS $0.25, Inline, Sales $147.30M Beat $143.79M Estimate

Cryptocurrency markets are stable on Wednesday morning, with Bitcoin retreating to $106,000 after tapping $108,000 during Asia trading hours.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$106,244.58</td>
<td>+0.95%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,519.57</td>
<td>+0.13%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$168.03</td>
<td>+0.7%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.33</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2251</td>
<td>+1.9%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001443</td>
<td>+1.1%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum daily active addresses increased by 5.5% and 6.4%, respectively. BTC's large transaction volume went up by 10%.</li>
<li>Coinglass data shows 90,882 traders were liquidated in the past 24 hours for $257.09 million.</li>
<li>SoSoValue data shows $329 million in net inflows into spot Bitcoin ETFs and $64.9 million net inflows into spot Ethereum ETFs. </li>
</ul>
Trader Notes: Nic Puckrin, co-founder of CoinBureau, noted a wave of limit orders above $107,500 caused a sharp rejection at $108,000. He warned that the road to new all-time highs would remain volatile.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Lots of limit orders above $107.5k hit which led to a hard rejection at $108k. The route to all-time-highs is going to be choppy &#x1f440; <a href="https://t.co/2r29qOMjxm">pic.twitter.com/2r29qOMjxm</a>
&mdash; Nic (@nicrypto) <a href="https://twitter.com/nicrypto/status/1925105899963633666?ref_src=twsrc%5Etfw">May 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
CoinBureau also <a href="https://x.com/coinbureau/status/1925083657103868162">highlighted</a> that $1.01 billion in short positions are set to be liquidated at $108,000. If triggered, these shorts could fuel a rapid BTC surge as bears are forced to buy back into the market.
Dogecoin continues to defy broader market inertia. Javon Marks compared the current cycle to previous bull runs and projected a 215% rally, taking DOGE to a minimum of $0.73905.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">By Dogecoin&#39;s previous bull cycles and its similar setup this cycle, another nearly +215% increase to $0.73905, AT THE MINIMUM, can be on the way &#x26a1;&#xFE0F;.<a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> <a href="https://t.co/0CQt5EPADZ">pic.twitter.com/0CQt5EPADZ</a>
&mdash; JAVON&#x26a1;&#xFE0F;MARKS (@JavonTM1) <a href="https://twitter.com/JavonTM1/status/1925025654963073215?ref_src=twsrc%5Etfw">May 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
IncomeSharks <a href="https://x.com/IncomeSharks/status/1924931752252080327">remains</a> bullish on Ethereum, sticking to a $3,000 target—and even eyeing $4,000, provided the $2,515 support holds. He admitted his only regret is not being more bullish on ETH earlier.
Crypto Bitlord made a bold <a href="https://x.com/crypto_bitlord7/status/1925104825114755164">prediction</a>: "If Bitcoin hits $400,000, then XRP at $80 becomes not just possible, but easy." He dismissed ETH and Solana as "too safe," suggesting they won't produce the generational wealth this cycle could offer.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45525006/bitcoin-is-about-to-make-a-golden-cross-what-happens-next">Bitcoin Is About To Make A Golden Cross: What Happens Next?</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Dogecoin Green But XRP Struggling On Wednesday Morning

Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD)
Trial is sponsored by the University of North Carolina (UNC) and supported by a grant from the U.S. Department of Defense
Topline results from the trial are expected in the second half of 2026
CHATHAM, N.J., May 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the first patient has been dosed in the Phase 2, investigator-initiated OASIS trial to evaluate TNX-102 SL in reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD). The trial is sponsored by the University of North Carolina (UNC) Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense (DoD).
The Optimizing Acute Stress Reaction Interventions with TNX-102 SL (OASIS) trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients presenting to the emergency department (ED) after a motor vehicle collision (MVC). The trial plans to enroll approximately 180 MVC-trauma survivors at ED study sites around the U.S. Participants will be randomized in the ED to receive a two-week course of either TNX-102 SL 5.6 mg or placebo.
The OASIS trial will build upon a foundation of knowledge and infrastructure developed through the UNC-led, $40 million AURORA initiative. AURORA is a major national research initiative to improve the understanding, prevention and recovery of individuals who experience a traumatic event. AURORA is supported by funding from the National Institutes of Health (NIH), leading brain health nonprofit One Mind, private foundations, and partnerships with leading tech companies, such as Mindstrong Health and Verily Life Sciences, the healthcare arm of Alphabet, the parent company of Google.
Acute and chronic stress disorders can affect both civilian and military populations. According to the National Center for PTSD, in the U.S. about 60% of men and 50% of women experience at least one trauma in their lives In the U.S. alone, one-third of ED visits (40-50 million patients per year) involve evaluation after trauma exposures, and in a 2014 study involving 3,157 US veterans, 87% reported exposure to at least one potentially traumatic event during their service. Moreover, as many as 500,000 U.S. troops who served in wars between 2001 and 2015 were diagnosed with PTSD. Currently, no medication is available in the immediate aftermath of traumatic events to treat the initial reaction and support long term health via a post-trauma clinical trajectory that prevents development or worsening of ASD, thereby also preventing PTSD.

TNXP

Tonix Pharma Announces First Patient Dosed In Phase 2, Investigator-Initiated OASIS Trial To Evaluate TNX-102 SL In Reducing Severity Of ASR And Frequency Of ASD

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">B&amp;G Foods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, B&amp;G Foods reported worse-than-expected first-quarter financial results and cut its FY25 adjusted EPS guidance below estimates. Also, the company cut its FY25 sales guidance. Casey Keller, President and Chief Executive Officer of B&amp;G Foods, said, &#8220;Our first quarter results reflect the challenging environment in the packaged foods industry at the start of 2025, including the impact of retailer inventory reductions and a shift in Easter timing into the second quarter. While January and February were especially difficult, recent net sales in March, April and early May have begun to show stabilizing trends versus last year.&#8221; The company's stock fell around 38% over the past month and has a 52-week low of $4.06.</li>
<li>RSI Value: 21.5</li>
<li>BGS Price Action: Shares of B&amp;G Foods fell 4.5% to close at $4.21 on Tuesday.</li>
<li>Edge Stock Ratings: 10.18 Momentum score with Value at 41.61. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/BGS"><img loading="lazy" decoding="async" width="473" height="175" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035653/image-256.png" alt="" class="wp-image-922355" style="width:343px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035653/image-256.png 473w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035653/image-256-300x111.png 300w" sizes="(max-width: 473px) 100vw, 473px" /></a></figure>
<h3 class="wp-block-heading">Forafric Global PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRI#NASDAQ">AFRI</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On April 4, Forafric Global named CEO Khalid Assari as Chairman of Board, replacing Saad Bendidi. &#8220;I am honored to take on the role of Chairman and look forward to working closely with the Board and leadership team to advance Forafric Global&#8217;s mission and strategic goals,&#8221; said Mr. Assari. The company's stock fell around 9% over the past month and <a href="https://www.benzinga.com/quote/AFRI">has a 52-week low</a> of $7.54.</li>
<li>RSI Value: 15.6</li>
<li>AFRI Price Action: Shares of Forafric Global fell 0.1% to close at $7.78 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0521">AFRI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0521"><img loading="lazy" decoding="async" width="916" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035802/image-257.png" alt="" class="wp-image-922356" style="width:584px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035802/image-257.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035802/image-257-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035802/image-257-768x689.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">Paranovus Entertainment Technology Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVS#NASDAQ">PAVS</a>)</h3>
<ul class="wp-block-list">
<li>On April 29, Paranovus Entertainment Technology said it regained Nasdaq compliance. The company's stock fell around 26% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/PAVS">low of $0.32</a>.</li>
<li>RSI Value: 28.4</li>
<li>PAVS Price Action: Shares of Paranovus Entertainment Technology fell 3% to close at $0.98 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0521">PAVS shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0521"><img loading="lazy" decoding="async" width="875" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035851/image-258.png" alt="" class="wp-image-922357" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035851/image-258.png 875w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035851/image-258-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/21035851/image-258-768x722.png 768w" sizes="(max-width: 875px) 100vw, 875px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45535402/target-lowes-and-3-stocks-to-watch-heading-into-wednesday">Target, Lowe&#8217;s And 3 Stocks To Watch Heading Into Wednesday</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

AFRI

PAVS

Top 3 Defensive Stocks That Are Preparing To Pump This Month

FEAM

5E Advanced Material Announced That It Has Achieved Another Developmental Milestone, Completing Equipment Testing For All Major Processes Of The Commercial Design For Its Large-scale Boron Facility

Expanded access reduces friction in virtual card acceptance for suppliers and their customers
Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), a global leader in digital payments, announced the general availability of its innovative product, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fusa.visa.com%2Fproducts%2Far-manager.html&amp;esheet=54257808&amp;newsitemid=20250521173856&amp;lan=en-US&amp;anchor=Visa+AR+Manager%2C&amp;index=1&amp;md5=c1e61db2a56312ec2d20e893565a0d0d">Visa AR Manager,</a> in the United States. Visa AR Manager is designed to grow and maintain existing card volume by automating the virtual card transaction process, addressing a significant pain point for suppliers accepting commercial credentials.
Visa AR Manager streamlines the virtual card transaction process by retrieving card account details, initiating authorization and clearing steps on the supplier's behalf, and then providing meaningful and timely reconciliation data to close out invoices in the supplier's ERP system. This automation revolutionizes the way virtual card transactions are managed, simplifying the process and reducing manual touchpoints for merchants, allowing them to focus on core business activities.

Visa Announces General Availability Of Visa AR Manager In US

Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) raises FY2026 sales outlook from $5.17 billion-$5.31 billion to $5.29 billion-$5.42 billion vs $5.24 billion estimate.

Guidance

Dycom Industries Raises FY2026 Sales Guidance from $5.17B-$5.31B to $5.29B-$5.42B vs $5.24B Est

Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) is looking for Q2 GAAP EPS of $2.74-$3.05 vs $2.84 analyst estimate. sees sales of $1.380 billion-$1.430 billion vs $1.36 billion analyst estimate.

Dycom Industries Sees Q2 GAAP EPS $2.74-$3.05 vs $2.84 Est; Sees Sales $1.380B-$1.430B vs $1.36B Est

Agreements Bolster AES' Position as the Energy Partner of Choice for Corporate Customers
ARLINGTON, Va., May 21, 2025 /PRNewswire/ -- The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) today announced that it has entered into two long-term Power Purchase Agreements (PPA) to support Meta's data centers with 650 MW of solar projects that AES is bringing online in the Southwest Power Pool (SPP) market.
In addition to supporting Meta's goals, these projects will provide employment opportunities and economic benefits to communities in Texas and Kansas, creating hundreds of construction jobs and contributing millions in long-term tax revenue to support local schools and counties.
 &nbsp;

AES Corp. Enters Into Two Long-Term Power Purchase Agreements To Support Meta's Data Centers With 650 MW Of Solar Projects In Texas And Kansas

Jefferies analyst David Chiaverini initiates coverage on Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Buy rating and announces Price Target of $20.

Price Target

Initiation

Analyst Ratings

HBAN

Jefferies Initiates Coverage On Huntington Bancshares with Buy Rating, Announces Price Target of $20

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Sphere 3D (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANY#NASDAQ">ANY</a>) with a Buy and maintains $3 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Sphere 3D, Maintains $3 Price Target

Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) reported quarterly earnings of $2.09 per share which beat the analyst consensus estimate of $1.69 by 23.67 percent. This is a 1.42 percent decrease over earnings of $2.12 per share from the same period last year. The company reported quarterly sales of $1.26 billion which beat the analyst consensus estimate of $1.19 billion by 5.40 percent. This is a 10.21 percent increase over sales of $1.14 billion the same period last year.

Dycom Industries Q1 EPS $2.09 Beats $1.69 Estimate, Sales $1.26B Beat $1.19B Estimate

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#NYSE">NRXS</a>), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules.
The offering is expected to close on or about May 22, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds from the offering are expected to be approximately $5.0 million, before deducting placement agent fees and other offering expenses payable by the Company. NeurAxis intends to use the net proceeds from the offering for working capital and general corporate purposes.

Offerings

NRXS

NeurAxis Enters Into Definitive Agreements For Purchase And Sale Of 1.5M Shares At $3.25/Shr In Registered Direct Offering

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.63) by 39.68 percent. This is a 50 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $2.44 million which missed the analyst consensus estimate of $4.42 million by 44.67 percent. This is a 41.67 percent decrease over sales of $4.19 million the same period last year.

Earnings Misses

EVGN

Evogene Q1 EPS $(0.38) Beats $(0.63) Estimate, Sales $2.44M Miss $4.42M Estimate

Benchmark analyst Cody Acree reiterates Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and maintains $6 price target.

INDI

Benchmark Reiterates Buy on Indie Semiconductor, Maintains $6 Price Target

Compass Point analyst Casey Alexander downgrades Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) from Neutral to Sell and lowers the price target from $6 to $5.75.

Downgrades

PNNT

Compass Point Downgrades Pennant Park Investment to Sell, Lowers Price Target to $5.75

BLCO

Bausch + Lomb Announced The U.S. Launch Of LUMIFY Preservative Free Redness Reliever Eye Drops, The First And Only Preservative-free Over-the-counter Eye Drops With Low-dose Brimonidine Tartrate 0.025% That Relieve Redness Of The Eye Due To Minor Eye Irritations

Guidance The company today issued its fiscal year 2026 (FY26) revenue growth and EPS guidance.
The company is guiding to FY26 organic revenue growth of approximately 5%. The organic revenue growth guidance excludes the impact of foreign currency exchange and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY26 revenue growth on a reported basis would be in the range of 4.8% to 5.1%.
Excluding the potential impacts from increased tariffs, Medtronic expects FY26 diluted non-GAAP EPS growth to be approximately 4%. This includes an expectation for non-GAAP operating profit to grow faster than organic revenue, partially offset by increased interest and tax expense. Including a potential impact from tariffs as detailed in the company's earnings presentation, Medtronic is guiding FY26 diluted non-GAAP EPS in the range of $5.50 to $5.60. The lower end of the EPS range assumes that the bilateral US/China tariffs resume at the higher rates following the 90 day pause, while the higher end of the EPS range assumes that the bilateral US/China tariffs currently in effect during the pause remain in place through fiscal year 2026.
"Our fiscal 2026 guidance reflects increasing revenue growth contribution from our key growth drivers, and increased investment to support their growth, leading to leveraged operating profit growth pre-tariffs. In addition, the team has rallied to identify opportunities to offset a large portion of tariffs, and we have high confidence in our ability to execute additional mitigation efforts," said Thierry Piéton, Medtronic chief financial officer, who joined the company on March 3, 2025. "This is an exciting time to join Medtronic. I am energized by the opportunities for durable growth and value creation ahead of us."

Medtronic Sees FY2026 Adj EPS $5.50-$5.60 Vs $5.83 Est., Sees 5% Organic Revenue Growth

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) with a Buy and maintains $60 price target.

DTIL

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target

Press Releases

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

Comments

Aquestive Therapeutics

뉴스

파트너 / 기고자

벤징가 글로벌